New Real-World Data Show High Rate of Patient Adherence to Tepezza for Thyroid Eye Disease (TED)
Horizon Therapeutics announced findings of a real-world adherence analysis of Tepezza for the treatment of TED at the American Academy of Ophthalmology Annual Meeting (AAO 2021). Tepezza is the first and only medicine approved by the FDA for the treatment of TED—a serious, progressive and potentially vision-threatening rare autoimmune disease.1
The analysis found that over 90% (n=995) of people who were prescribed Tepezza for TED went on to complete all eight infusions, indicating a high level of adherence to Tepezza in clinical practice. The study evaluated 1,101 people living with TED (71% female, mean age 58 years) who started treatment with Tepezza prior to July 2020. Non-compliance was low at approximately 1% (n=15). Only 8% (n=84) reported that they discontinued because of adverse events (AEs). The most common AEs reported in patients who discontinued due to an AE were consistent with observations in the Tepezza clinical trials.
“When considering treatment options, it is critical to balance desired efficacy with the potential for adverse events or other factors that may hinder adherence to treatment,” Roger A. Dailey, MD, FACS, study investigator and professor of ophthalmology, oculofacial plastic surgery and dermatology, Casey Aesthetic Facial Surgery Center at Oregon Health & Science University’s Casey Eye Institute, said in a company news release. “These results, which show patients are committed to finishing this therapy for Thyroid Eye Disease, should give physicians further confidence in medical management of this devastating condition.”
“It is encouraging to see the high rate of adherence that we observed in the clinical trials has continued in real world clinical practice, and that there were very few discontinuations due to adverse events,” said Jeffrey W. Sherman, MD, FACP, executive vice president, chief medical officer, Horizon. “These results provide important insights as physicians make treatment decisions with their patients. We know from our clinical trials the importance of completing all infusions as prescribed, as patients who completed the full course of therapy saw reduced eye bulging, improved double vision, and less eye pain, redness and swelling.”
References:
1. Karsten Klabe ‚‘‘Clinical Results of AcrivaUD Trinova Pro C Adaptive®“: